Undifferentiated carcinoma of pancreas with osteoclastic giant cells along with PanIN in a diabetic female- A case report

Lakshmi Priya U¹, Noushad Babu PK², Asiq Sideeque¹

¹Department of Pathology, Mes Medical College, Palachode P.O, Perinthalmanna, Kerala, India
²Department of gasrosurgery, Alshifa hospital, Perinthalmanna, Kerala, India.

Keywords:
Osteoclastic; Pancreas; Sarcomatoid carcinoma; Undifferentiated;

ABSTRACT

Undifferentiated carcinoma of pancreas with osteoclastic giant cells is a rare tumor. The prognosis is slightly better than usual anaplastic carcinoma. It is said to have an epithelial origin. We present a case of 61-year-old female who presented with features of cholangitis and on evaluation found to have pancreatic mass. Pancreatic intraepithelial neoplasia was also present in our case, which is a feature less commonly noted in published literature.

INTRODUCTION

Undifferentiated carcinoma (anaplastic carcinoma) is a malignant neoplasm in which significant portion of the tumor does not show a definitive direction of differentiation.¹ A number of terms have been used to describe variants of undifferentiated carcinoma of the pancreas, including pleomorphic carcinoma, pleomorphic giant cell carcinoma, sarcomatoid carcinoma, spindle cell carcinoma, anaplastic carcinoma, undifferentiated carcinoma.¹-³ Undifferentiated carcinoma with osteoclastic giant cells of the pancreas (UC- OGC) is a distinctive tumor type in the pancreas. It is regarded as a variant of sarcomatoid carcinoma with striking chemotaxis of osteoclastic giant cells. The biologic nature of these tumors is yet to be unravelled. These tumors have been noted to coexist with ductal adenocarcinomas or mucinous cystic neoplasms (MCNs).³

CASE REPORT

A 61-year-old female who is a known case of diabetes mellitus, presented to gastroenterology OPD with
complaints of right hypochondral pain. Cholangitis was suspected and she underwent ERCP. During the procedure a mass was detected in the pancreas and there was obstruction in the bile duct for which stenting was done. Then she was referred to gastro-surgeon. She was found to have elevated CA19-9 (48; n<37 U/mL). CT showed an irregular mass lesion in the head of the pancreas (fig. 1A). Whipple resection was planned and intra-operatively tumor was seen involving superior mesenteric artery and seen very close to portal vein. Subsequently we received Whipple resection specimen. An ill-circumscribed, infiltrating grey white mass lesion in the neck of the pancreas extending to the head, measuring 3.5x 3x2cm (fig. 1B).

Sections showed a tumor (fig. 2A-D) arranged predominantly as sheets and focally as tubules and acini. Extensive areas show undifferentiated component with highly pleomorphic spindle cells/mononuclear cells arranged as sheets. Large areas of necrosis and hemorrhage seen and these areas were bordered by numerous osteoclasts like giant cells many of which had > 20 nuclei. Many scattered bizarre tumor cells were seen. Mitosis was 8-10/10hpf. Section from pancreatic duct showed pancreatic intraepithelial neoplasia 2 (fig2E and F).

Immunohistochemistry with CK7 and vimentin was done. The epithelial mucinous component and few mononuclear
spindle cells showed cytoplasmic positivity. Mononuclear spindle cells and osteoclast-like giant cells showed strong cytoplasmic positivity for vimentin (fig. 3).

DISCUSSION

Undifferentiated pancreatic carcinoma with osteoclast-like giant cells was initially described in 1968 by Juan Rosai as a distinct tumor type and a variant of undifferentiated carcinoma defined by conspicuous presence of giant cells resembling “osteoclastic cells”. This tumor is now well recognized as a distinct entity of the pancreas, although it is very rare. This is a rare neoplasm composed of round to spindle-shaped, highly pleomorphic neoplastic mononuclear cells and large, non-neoplastic multinucleated histiocytic giant cells. The osteoclast-like giant cells can have increase phagocytic active and may contain haemosiderin.

Pancreatic UC-OGC is more common in middle-aged and elderly patients, 94% of whom are over 50 years of age, and the average age is 63 years. Most patients are females (male: female=7:10). The clinical symptoms are atypical, and mostly manifest as upper abdominal pain and/or weight loss. Loss of appetite, abnormal taste, nausea, steatorrhea, and some other gastrointestinal symptoms have also been reported in some cases. The neoplasms are mostly located in the body and tail of the pancreas. UC-OGCs are nodular and promote marginal growth. Despite the large volume, tissue infiltration and lymph node metastases are not common. The prognosis of the tumor is poor and the median survival is only 12 months.

There is much debate in the literature as to the origin of the tumor, with many authors favoring mesenchymal origin, and others favoring epithelial origin. There is overwhelming evidence that the osteoclastic cells in this tumor are indeed osteoclastic cells, both by morphology, as well as immunoprofile (positive for CD68, negative for cytokeratins AE1/AE3 and p53, and had a low Ki-67 index) and thus are believed to be a benign population of
histocytic cell lineage, that is massively recruited to this distinctive sarcomatoid neoplasm. It is hypothesized that OGC recruitment is a result of chemotactic factors produced by the neoplastic cells. Most of the neoplastic mononuclear cells express vimentin, some express keratin and somelabel with antibodies to p53. In a study by Luchini et al it was purported that UC-OGC’s are variants of pancreatic ductal carcinoma (PDC) due to the presence of shared mutations in KRAS and other critical tumor suppressor genes commonly associated with PDC (TP53, CDKN2A and SMAD4).

CONCLUSIONS

It is important to recognize this entity as it has got slightly better prognosis compared to usual undifferentiated carcinoma. Worldwide further studies may be needed for defining treatment guidelines for this entity. This case had an additional component of Pan IN- 2 also which is a rare association with undifferentiated carcinoma. Our patient expired soon after the diagnosis.

Conflict of Interest: None

REFERENCES


DOI : 10.3126/jpn.v10i1.27297